Puma Biotech Investors Seek Class Cert. In Stock-Drop Case
Puma Biotechnology Inc. investors who lost money when clinical trial results undercut the biopharmaceutical company's prior statements about a cancer drug it was developing asked a California federal court Wednesday for...To view the full article, register now.
Already a subscriber? Click here to view full article